Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton Dickinson and Company

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics has unveiled BREASTEST Monitor, a new blood test designed to evalu...

BCAL launches blood test to monitor breast cancer recurrence

Stocks ended the week sharply lower as a stronger-than-expected May jobs report pushed bond yields higher and hit the market’s biggest winners. The...

The Week That Was, The Week Ahead: Macro and Markets, June 7

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Becton Dickinson (BDX), Agios Pharma (AGIO) and He...

Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Agios Pharma (AGIO) and Healthequity (HQY)

Becton Dickinson ( ($BDX) ) just unveiled an update. On May 6, 2026, BD voluntarily placed its ChloraPrep and PurPrep antiseptic products on ship h...

BD Resumes ChloraPrep Shipments Amid Ongoing FDA Review

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics has signed a validation agreement with Sonic Healthcare USA to opt...

BCAL Moves Toward U.S. Entry With Sonic Healthcare Validation Deal

Piper Sandler analyst Jason Bednar maintained a Hold rating on Becton Dickinson today and set a price target of $161.00. According to TipRanks, Bed...

Becton Dickinson (BDX) Gets a Hold from Piper Sandler

An update from GSH ( ($SG:BDX) ) is now available. GSH Corporation’s latest annual general meeting in Singapore highlighted its continuing focus on...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BDX	$143.98	+1.67%	6.23M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BDX	$143.98	+1.7%	6.23M
3
4
5
6

BDX

BDX

No Data Available

Get Becton Dickinson and Company Data in Excel

Get Becton Dickinson and Company Data in Excel